

ExpreS²ion will participate in key industry and investor events

Hørsholm, Denmark, September 20, 2022 – ExpreS²ion Biotech Holding AB's affiliate ExpreS²ion Biotechnologies ApS ("ExpreS²ion") will participate and hold presentations at key industry and investor events in the coming month. These include PIVAC-22, a forum covering the most recent advances in cancer immunotherapy (September 26-28) and Aktiedagen Lund (September 26).

By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS² technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company's [website](#).

Progress in Vaccination Against Cancer (PIVAC-22), September 26-28, Torino, Italy

Meet ExpreS²ion's VP of Preclinical Development, Dr. Mette Thorn, and hear the company's preclinical development partners from the University of Bologna present on "Prevention and therapy of metastatic HER-2+ mammary carcinoma with a human candidate HER-2 virus-like particle vaccine," in a forum covering the most recent advances in the field of cancer immunotherapy. More information and registration can be found on the [PIVAC-22 website](#).

Aktiedagen Lund, September 26 at 11:00 CET, Virtual

Join CEO of ExpreS²ion Biotechnologies Bent U. Frandsen for a live update at Aktiedagen in Lund. You can stream the event live or on demand via Aktiespararnas [YouTube Channel](#) or at [Aktiespararna.se/tv/live](https://aktiespararna.se/tv/live).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmq.se

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.